Emmaus Life Sciences, Inc.
EMMA
$0.01
$0.00-1.02%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.38M | 2.82M | 2.41M | 3.29M | 5.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.38M | 2.82M | 2.41M | 3.29M | 5.48M |
| Cost of Revenue | 247.00K | 150.00K | 225.00K | 309.00K | 394.00K |
| Gross Profit | 3.13M | 2.67M | 2.18M | 2.98M | 5.08M |
| SG&A Expenses | 1.90M | 2.98M | 2.99M | 3.40M | 4.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.20M | 3.19M | 3.39M | 3.85M | 4.66M |
| Operating Income | 1.18M | -370.00K | -980.00K | -557.00K | 821.00K |
| Income Before Tax | -1.50M | -1.73M | -2.33M | -1.74M | 1.83M |
| Income Tax Expenses | 579.00K | -590.00K | 4.00K | 6.00K | -1.00K |
| Earnings from Continuing Operations | -2.08M | -1.14M | -2.33M | -1.75M | 1.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.08M | -1.14M | -2.33M | -1.75M | 1.83M |
| EBIT | 1.18M | -370.00K | -980.00K | -557.00K | 821.00K |
| EBITDA | 1.19M | -366.00K | -975.00K | -552.00K | 826.00K |
| EPS Basic | -0.03 | -0.02 | -0.04 | -0.03 | 0.03 |
| Normalized Basic EPS | -0.01 | -0.02 | -0.02 | -0.02 | 0.02 |
| EPS Diluted | -0.03 | -0.02 | -0.04 | -0.03 | 0.03 |
| Normalized Diluted EPS | -0.01 | -0.02 | -0.02 | -0.02 | 0.02 |
| Average Basic Shares Outstanding | 63.87M | 63.87M | 63.87M | 63.86M | 63.87M |
| Average Diluted Shares Outstanding | 63.87M | 63.87M | 63.87M | 63.86M | 63.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |